April 08, 2026
11 11 11 AM
How Zendaya Convinced Her Mom to Get First Tattoo at 50
JD Vance arrives in Hungary to back Orbán’s re-election bid
Jennifer Lopez Details Chapter of “New Beginnings” in Easter Message
How rescue of US airman in remote part of Iran unfolded
Gabrielle Union’s Dad, Sylvester “Cully” Union Jr., Dead at 81
AI videos fuel rhetoric as Orbán bids for four more years in Hungary
Taylor Frankie Paul Bonds With Older Kids Amid Dakota Mortensen Drama
Rescue team in Iran face ‘harrowing and dangerous’ search for US crew member
Chris Rock Debuts New Relationship During PDA-Filled Stroll
Artemis II leaves Earth’s orbit on track for far side of the Moon
Latest Post
How Zendaya Convinced Her Mom to Get First Tattoo at 50 JD Vance arrives in Hungary to back Orbán’s re-election bid Jennifer Lopez Details Chapter of “New Beginnings” in Easter Message How rescue of US airman in remote part of Iran unfolded Gabrielle Union’s Dad, Sylvester “Cully” Union Jr., Dead at 81 AI videos fuel rhetoric as Orbán bids for four more years in Hungary Taylor Frankie Paul Bonds With Older Kids Amid Dakota Mortensen Drama Rescue team in Iran face ‘harrowing and dangerous’ search for US crew member Chris Rock Debuts New Relationship During PDA-Filled Stroll Artemis II leaves Earth’s orbit on track for far side of the Moon

Intranasal vaccine against H5 avian flu provokes broad immune response in adults in phase 1 trial

Three of five groups of eight participants each received low, medium, or high doses of the clade 2.1 influenza A/H5 (A/Indonesia/05/2005) recombinant hemagglutinin glycoprotein (rH5) vaccine combined with an adjuvant; one group received 100 µg of an unadjuvanted rH5 vaccine; and one group received placebo. All participants received an intramuscular H5 booster 6 months later.

Participants who received the adjuvanted vaccine had higher levels of protective antibodies (immunoglobulin [Ig] G and A), more memory immune cells, and a better ability to neutralize infected cells.

Only recipients of the boosted intranasal vaccine showed strong immune priming. Even without a booster, the intranasal vaccine triggered mucosal and systemic immunity, which other intranasal recombinant H5 flu vaccines have not achieved in clinical trials. It also was safe and well-tolerated.

The immune system’s ability to recognize multiple strains of H5N1 virus is key because they change over time, co-lead author Meagan Deming, MD, PhD, said in a university news release. “The use of the adjuvant also suggests this approach might allow for lower doses of the vaccine, which could make our current vaccine stocks available to more people in the event of an outbreak,” she said.

Corresponding author Justin Ortiz, MD, said that global transmission of H5N1 in animals, including spillover into people, underscores the need for effective countermeasures. “This trial shows that this intranasal, shelf-stable H5N1 vaccine could play a major role in pandemic preparedness, offering a practical and scalable way to help protect people from evolving strains of the virus,” he said.

11 thoughts on “Intranasal vaccine against H5 avian flu provokes broad immune response in adults in phase 1 trial

  1. Your blog is a testament to your dedication to your craft. Your commitment to excellence is evident in every aspect of your writing. Thank you for being such a positive influence in the online community.

  2. I just wanted to drop by and say how much I appreciate your blog. Your writing style is both engaging and informative, making it a pleasure to read. Looking forward to your future posts!

  3. Hello Neat post Theres an issue together with your site in internet explorer would check this IE still is the marketplace chief and a large element of other folks will leave out your magnificent writing due to this problem

  4. Your blog is a testament to your dedication to your craft. Your commitment to excellence is evident in every aspect of your writing. Thank you for being such a positive influence in the online community.

Leave a Reply

Your email address will not be published. Required fields are marked *